Beckley Psytech | search
Click here to view Beckley Psytech news from 60+ newspapers.
Bookmark or Share- Beckley Psytech to present data on BPL-003, a novel synthetic ...Beckley Psytech, the private, clinical-stage biopharmaceutical company developing effective, rapid-acting and accessible medicines for people living with mental health conditions, today announced that it will be presenting data on BPL-003, a novel synthetic intranasal formulation of 5-MeO-DMT benzoate, in two poster presentations at the ECNP ...
- Beckley Psytech · Working with patients in mindBeckley Psytech’s innovative approach to helping patients in need is focused on developing novel psychedelic therapies to improve patient outcomes.
- Team - Beckley PsytechDr. Rob Conley is the Chief Scientific Advisor at Beckley Psytech. He previously served as Senior Vice President at Eleusis and Chief Science Officer, Neuroscience at Eli Lilly and Co. Prior to that he had a long academic career, first at the University of Pittsburgh and then at the University of Maryland School of Medicine.
- Trials overview - Beckley PsytechTrials. We are currently investigating BPL-003 (our novel intranasal formulation of 5-MeO-DMT) and ELE-101 (our novel intravenous formulation of psilocin) for Treatment Resistant Depression, Major Depressive Disorder and Alcohol Use Disorder.
- About Us - Beckley PsytechBeckley Psytech was created to build upon the Foundation’s work by developing safe and effective psychedelic medicines for patients in need and integrating these treatments into mainstream medical practices.
More
